It definitely is a massive deterrence for many of the larger more conservative investors. However when the FDA approval arrives and the subsequent "hard numbers" are released to the market, this will be seen as a genuine pharmaceutical company, not merely a "weed stock", and finally we should see a proper valuation. In the meantime, the mismatch between the price and the fundamentals presents a major opportunity for the better researched investors IMO
It definitely is a massive deterrence for many of the larger...
-
- There are more pages in this discussion • 3,265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.005(1.18%) |
Mkt cap ! $761.8M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.5¢ | 41.5¢ | $2.435M | 5.697M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 819538 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 29052 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |